Ian Burr Division of Endocrinology and Diabetes, Department of Pediatrics.
Department of Pathology, Microbiology, and Immunology; and.
JCI Insight. 2021 Oct 8;6(19):e143245. doi: 10.1172/jci.insight.143245.
Autoimmune disease has presented an insurmountable barrier to restoration of durable immune tolerance. Previous studies indicate that chronic therapy with metabolic inhibitors can reduce autoimmune inflammation, but it remains unknown whether acute metabolic modulation enables permanent immune tolerance to be established. In an animal model of lupus, we determined that targeting glucose metabolism with 2-deoxyglucose (2DG) and mitochondrial metabolism with metformin enables endogenous immune tolerance mechanisms to respond to tolerance induction. A 2-week course of 2DG and metformin, when combined with tolerance-inducing therapy anti-CD45RB, prevented renal deposition of autoantibodies for 6 months after initial treatment and restored tolerance induction to allografts in lupus-prone mice. The restoration of durable immune tolerance was linked to changes in T cell surface glycosylation patterns, illustrating a role for glycoregulation in immune tolerance. These findings indicate that metabolic therapy may be applied as a powerful preconditioning to reinvigorate tolerance mechanisms in autoimmune and transplant settings that resist current immune therapies.
自身免疫性疾病对持久免疫耐受的恢复构成了难以逾越的障碍。先前的研究表明,代谢抑制剂的慢性治疗可以减轻自身免疫性炎症,但尚不清楚急性代谢调节是否能使永久性免疫耐受得以建立。在狼疮动物模型中,我们确定使用 2-脱氧葡萄糖(2DG)靶向葡萄糖代谢和二甲双胍靶向线粒体代谢,可以使内源性免疫耐受机制对诱导耐受做出反应。为期 2 周的 2DG 和二甲双胍治疗,与诱导耐受的抗 CD45RB 治疗联合使用,可在初始治疗后 6 个月预防自身抗体在肾脏中的沉积,并使狼疮易感小鼠的同种异体移植物恢复诱导耐受。持久免疫耐受的恢复与 T 细胞表面糖基化模式的变化有关,这表明糖调节在免疫耐受中起作用。这些发现表明,代谢疗法可作为一种强大的预处理手段,在抵抗当前免疫疗法的自身免疫和移植环境中重新激活耐受机制。